The acquisition of Auspex strengthens Teva’s leadership position in CNS and advances us into significantly underserved movement disorder markets. This transaction represents a first major step in generating growth and creating value for our shareholders through business development in 2015.

Erez Vigodman

President and Chief Executive Officer

Read More >

“We are creating breakthroughs in neurodegeneration. Teva’s National Network of Excellence will contribute to the quality of life of us all.”

Dr. Daniel Offen

Tel Aviv University

Discover more >

“Copaxone and Azilect came from Israeli universities. Why wouldn’t we tap into this incredible expertise and innovation of Israeli Universities to find the next jewels.”

Dr. Michael Hayden

President of Global R&D andChief Scientific Officer, Teva

Discover more >

“I hope the challenge I overcome by doing the ride serves as an inspiration to those that have MS.“

Matt Ferko

Athlete and MS Patient

Discover more >

"Our single-minded focus, through the skills of our scientists, is to ensure that we bring essential generic medicines of high quality to the greatest number of in the fastest time possible."

Elizabeth Kogan

SVP, Global Generics R&D, Teva

Discover more >

"It is a great privilege to providequality medicines that help people."

Dror Gefen

QA Manager, Plantex-Abic

Discover more >

“Today we can understand the processes resultingin disease and response to drugs in individual patients with greater precision than ever before.”

Dr. Iris Grossman

Global Head, Personalized Medicineand Pharmacogenomics, Teva

Discover more >

“Our NTE process reflects our expertise ingenerics and specialty drugs, and the synergiescreated when these capabilities are integrated.”

Dr. Michael Hayden

President of Global R&D andChief Scientific Officer, Teva

Discover more >

"Our collaboration with Teva will contribute greatly to the Korean pharmaceutical industry by supplying innovative medicines at affordable prices."

Young-Jin Kim

CEO & Chairman, Handok

Discover more >

“In China there is an increasing demand forquality generic medication. We were very impressedby Teva's oncology, CNS and respiratory portfolio."

Yin-Li

Deputy Minister and head of theChinese Food and Drug Administration (CFDA)

Discover more >

“There is no greater pleasure than in sharingour knowledge with younger generations.”

ArinaChaushu

Teva Global R&D

Discover more >

“Our DNA is the combination of P&G and Teva. Our mission is to understand what people wantand need, and then find innovative ways to deliver that.”

Briain de Buitlier

CEO PGT Healthcare

Discover more >

“We are excited to develop environmentally friendly technologies to create a healthier world for our customers worldwide.“